Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Non-cash Items (2023 - 2025)

Compass Therapeutics' Non-cash Items history spans 3 years, with the latest figure at $13.7 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 2266.15% year-over-year to $13.7 million; the TTM value through Dec 2025 reached $13.7 million, up 2266.15%, while the annual FY2025 figure was $13.7 million, 2266.15% up from the prior year.
  • Non-cash Items for Q4 2025 was $13.7 million at Compass Therapeutics, up from $11.6 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $21.5 million in Q1 2025 and bottomed at $11000.0 in Q4 2023.
  • The 3-year median for Non-cash Items is $11.6 million (2025), against an average of $11.3 million.
  • The largest annual shift saw Non-cash Items surged 5163.64% in 2024 before it decreased 3.14% in 2025.
  • A 3-year view of Non-cash Items shows it stood at $11000.0 in 2023, then soared by 5163.64% to $579000.0 in 2024, then soared by 2266.15% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Non-cash Items are $13.7 million (Q4 2025), $11.6 million (Q3 2025), and $19.5 million (Q2 2025).